Law Offices of Howard G. Smith Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

A class action lawsuit has been filed against ADMA Biologics, Inc. for alleged securities fraud. According to a Culper Research report, the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The stock fell 29.1% following the allegations. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can participate in the lawsuit, with a deadline of August 10, 2026 to file a lead plaintiff motion.